Pharma Revision Will Hasten EU’s R&D Decline, Says EFPIA’s New Presidency Team

The European pharma industry group fears planned cuts in regulatory data protection and orphan drug exclusivity periods will hit innovation but says it is ready to work with legislators to close what it sees as an R&D gap between the EU on the one hand and the US and Asia on the other.